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Statement of findings
The immunodominant T-cell epitope that is involved in collagen-induced arthritis (CIA) is the
glycosylated type II collagen (CII) peptide 256–270. In CII transgenic mice, which express
the immunodominant CII 256–270 epitope in cartilage, the CII-specific T cells are
characterized by a partially tolerant state with low proliferative activity in vitro, but with
maintained effector functions, such as IFN-g secretion and ability to provide B cell help.
These mice were still susceptible to CIA. The response was mainly directed to the
glycosylated form of the CII 256–270 peptide, rather than to the nonglycosylated peptide.
Tolerance induction was rapid; transferred T cells encountered CII within a few days. CII
immunization several weeks after thymectomy of the mice did not change their susceptibility
to arthritis or the induction of partial T-cell tolerance, excluding a role for recent thymic
emigrants. Thus, partially tolerant CII autoreactive T cells are maintained and are crucial for
the development of CIA.
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APC = antigen-presenting cell; CFSA = 5- (and 6)-carboxyfluorescein diacetate succinimidyl ester; CIA = collagen-induced arthritis; CII = collagen
type II; EAE = experimental allergic encephalomyelitis; ELISA = enzyme-linked immunosorbent assay; ELISPOT = enzyme-liked immunospot; 
LNC = lymph node cell; MBP = myelin basic protein; MHC = major histocompatibility complex; MMC = mutated mouse collagen; RA = rheumatoid
arthritis; TCR = T-cell receptor.
Introduction: A discussion is ongoing regarding the possible role
of cartilage-directed autoimmunity as a part of the pathogenesis
of rheumatoid arthritis (RA). One possibility is that the association
of RA with shared epitope-expressing DR molecules reflects a
role for major histocompatibility complex (MHC) class II molecules
as peptide receptors, and that the predilection of the inflammatory
attack for the joint indicates a role for cartilage as a source of the
antigenic peptides. A direct role for CII in the development of
arthritis is apparent in the CIA model, in which a definite role for
MHC class II molecules and a role for CII-derived peptides have
been demonstrated [1–3]. Remarkably, it was found that the
identified MHC class II molecule in the CIA model Aq has a
structurally similar peptide binding pocket to that of the shared
epitope, expressing DR4 molecules [4]. In fact, DR4
(DRB1*0401) and DR1 (DRB1*0101) transgenic mice are
susceptible to CIA because of an immune response to a peptide
that is almost identical to that which is involved in Aq-expressing
mice [5,6]. They are both derived from position 260–273 of the
CII molecule; the peptide binds to the Aq molecule with isoleucine
260 in the P1 pocket, but with phenylalanine 263 in the P1
pocket of the DR4 and DR1 molecules.
Although these findings do not prove a role for CII in RA, they
show that such recognition is possible and that there are
structural similarities when comparing mouse with human.
However, there are also strong arguments against such a
possibility. First, arthritis can evolve without evidence for a
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cartilage-specific autoimmunity, as seen with various adjuvant-
induced arthritis models [7,8] and in several observations using
transgenic animals with aberrant immunity to ubiquitously
expressed proteins [9–11]. Moreover, the MHC association in
the adjuvant arthritis models correlates with severity of the
disease rather than susceptibility [7,8], as has also been
observed in RA [12]. Second, it has not been possible to
identify the CII-reactive T cells from RA joints, or to achieve a
strong and significant CII proliferative response from T cells
derived from RA joints. Most recently these negative
observations were corroborated using DR4+CII peptide
tetramer reagents [13]. On the other hand, it has also been
difficult to isolate autoreactive CII-specific T cells from CIA, and
it can be anticipated that, even in the CIA model, T cells that are
specific for CII will be hard to find in the joints [4].
We believe that the explanations for these observations in both
experimental animals and humans are related to tolerance. The
CIA model in the mouse is usually induced with heterologous
CII, and is critically dependent on an immune response to the
glycosylated CII peptide 256–270, which is bound to the MHC
class II Aq molecule. In CII transgenic mice, expressing the
heterologous (rat) form of the immunodominant CII 256–270
epitope in cartilage, we observed partial T-cell tolerance. This
tolerance is characterized by a low proliferative activity, but with
maintained effector functions such as production of IFN-g and
the ability to give help to B cells to produce anti-CII IgG
antibodies [14]. Interestingly, these mice were susceptible to
arthritis. However, a possibility was that T cells that had newly
emerged from the thymus and that were not yet tolerized when
the mice were immunized with CII led to the induction of
arthritis. We have now addressed this possibility and found that
induction of tolerance occurs within a few days, and that mice
lacking recent thymic emigrants (ie thymectomized mice) display
partially tolerant T cells and susceptibility to arthritis to the same
extent as nonthymectomized mice. In addition we found that
T cells that are reactive with the nonmodified peptides are
relatively more affected by tolerance than T cells that are
reactive with the more immunodominant glycosylated variants.
Objectives: To investigate the possibility that T cells that are
naturally tolerant to the cartilage protein CII are involved in the
development of arthritis, and to exclude a role for nontolerized
recent thymic T-cell emigrants in the development of arthritis.
Materials and methods: A mutated mouse CII, expressing
glutamic acid instead of aspartic acid at position 266, was
expressed in a transgenic mouse called MMC (mutated mouse
collagen) that has been described earlier [14]. The mice were
thymectomized, or sham-operated, at 7 weeks of age and
allowed to recover for 4 weeks before being immunized with rat
CII in complete Freund’s adjuvant. Arthritis development was
recorded and sera analyzed for anti-CII IgG, IgG1 and IgG2a
levels. To assay T-cell effector functions, other MMC and
control mice were immunized in the hind footpads with rat CII
in complete Freund’s adjuvant, and the draining popliteal lymph
nodes were taken 10 days later. The lymph node cells (LNCs)
were used for proliferation assay, IFN-g enzyme-linked
immunosorbent assay (ELISA) and B-cell enzyme-linked
immunospot (ELISPOT). For the proliferation assay, 106 cells
were put in triplicate cultures in microtitre wells together with
antigen and incubated for 72 h before thymidine-labelling and
harvesting 15–18 h later. For IFN-g ELISA analysis, supernatant
from the proliferation plates was removed before harvesting
and used in an ELISA to quantify the amount of IFN-g produced
[15]. B-cell ELISPOT was performed to enumerate the number
of cells producing anti-CII IgG [16].
T-cell lines that were reactive towards rat CII were established
by immunization with rat CII. An established T-cell line that was
reactive with CII and specific for the CII 256–270 peptide was
restimulated with freshly collected, irradiated, syngenic spleen
cells and rat CII for 3 days followed by 2 weeks of IL-2
containing medium. Immediately before transfer, the cells were
labelled with the cytoplasmic dye 5 (and 6)-carboxyfluorescein
diacetate succinimidyl ester (CFSE) [17]. Labelled cells (107)
were injected intravenously into transgenic MMC mice and
nontransgenic littermates. The mice were killed 4 days after cell
transfer, and the concentration of CFSE-labelled cells was
determined by flow cytometry.
Results and discussion: To investigate whether and how
quickly CII-reactive T cells will encounter CII in vivo, an
established T-cell line that is reactive towards rat CII was
labelled with the cytoplasmic dye CFSE and transferred into
MMC-QD and control mice. Four days later the mice were
killed, and it was found that MMC-transgenic mice had
dramatically fewer CFSE-labelled cells in the spleen than did
nontransgenic littermates (0.11% compared with 0.57%).
Similarly, reduced numbers of CFSE-positive cells were
observed in blood. This indicates that the T cells encountered
the mutated CII that was present in the cartilage of MMC mice,
but not in the nontransgenic littermates. Presumably, CII from
cartilage is spread by antigen-presenting cells (APCs) to
peripheral lymphoid organs. This observation also suggests
that newly exported T cells from the thymus will be tolerized to
CII in the periphery within less than 4 days.
To further investigate whether the MMC mice harbours naïve or
tolerized T cells, the mice were immunized with CII at different
time points after thymectomy that were well in excess of the
times required for their encounter with CII. After 10 days, the
response was analyzed in vitro towards both the nonglycosylated
and the glycosylated CII 256–270 peptides as well as towards
purified protein derivative. The galactosylated form of the peptide
(Fig. 1) was used because this is the most immunodominant
modification [18]. In contrast to control mice, LNCs from
transgenic mice did not proliferate significantly towards the
nonglycosylated peptide, indicating that these cells have been
specifically tolerized, which is in accordance with earlier
observations [14]. A reduced, but still significant proliferation
was also observed toward the immunodominant glycosylated CII
peptide. Most important, however, was that the proliferative
response in the MMC mice did not decrease after thymectomy.
Similarly, a significant IFN-g production towards the glycosylated
CII peptide was observed in the MMC mice. The response was
somewhat reduced compared with that observed in
nontransgenic littermates, and this was especially true for theresponse toward the nonglycosylated peptide. Again, no
decrease in the MMC response by thymectomy was observed.
Taken together, the T-cell response in transgenic mice was
reduced in comparison with that in the nontransgenic littermates.
Furthermore, the response in transgenic animals did not
decrease by thymectomy (4 or 8 weeks before immunization),
showing that autoreactive T cells are still maintained (and partially
tolerized) with significant effector functions at least up to 8
weeks after thymectomy, excluding an exclusive role for recent
thymic emigrants in the autoimmune response towards CII.
To investigate whether thymectomized mice, lacking recent CII-
specific thymic emigrants, were susceptible to CIA, mice were
immunized with CII 4 weeks after thymectomy and were
observed for arthritis development during the following 10
weeks. Clearly, the thymectomized MMC mice were susceptible
to arthritis (five out of 18 developed arthritis; Fig. 2), and no
significant differences in susceptibility between thymectomized
and sham-operated mice, or between males and females, were
seen. In accordance with earlier results [14], MMC transgenic
mice had a significantly reduced susceptibility to arthritis as
compared with the nontransgenic littermates (P<0.0001 for
arthritic scores, disease onset and incidence). All mice were bled
at 35 days after immunization, and the total levels of anti-CII IgG
were determined. Transgenic mice developed levels of anti-CII
IgG significantly above background, but the antibody titres were
lower than in nontransgenic littermates (P<0.0001). No effect
on the antibody levels by thymectomy was observed, nor did the
thymectomy affect the distribution of IgG1 versus IgG2a titres,
indicating that the observed tolerance is not associated with a
shift from a T-helper-1- to a T-helper-2-like immune response.
These findings show that T cells that are specific for a tissue-
specific matrix protein, CII, are partially tolerized within a few
days after thymus export and that these tolerized cells are
maintained after thymectomy. Most important, mice that lack
newly exported CII reactive T cells are still susceptible to CIA,
suggesting that the partially tolerant T cells are involved in
development of arthritis.
In the light of these data it is possible to explain some of the
findings in RA. T-cell reactivity to CII has been shown in RA
patients, but with a very weak proliferative activity [19,20]. This
is fully compatible with observations in mouse and rat CIA
when autologous CII, and not heterologous CII, are used for
immunization. This is particularly true if the responses are
recorded during the chronic phase of disease, in which the
antigen-specific T-cell responses seem to be suppressed in
both humans and experimental animals. These observations
were confirmed in a recent report [21] in which it was shown
that CII-reactive T-cell activity could be detected in RA patients
if IFN-g production but not proliferation was measured. In the
present studies in mice the strongest response is seen towards
post-translational modifications of the peptide. Because the
T-cell contact points are the same whether the peptide is
bound to DR4 or to Aq, it is fully possible that post-translational
modifications of the peptide also plays a significant role in
humans [22]. The fact that IgG antibodies specific for CII are
found in many RA patients could be explained by maintained
B-cell helper functions of CII-reactive T cells. In fact, it has
been reported [23,24] that the occurrence of IgG antibodies to
CII is associated with shared epitope DR4 molecules. These
observations are thus compatible with a role for CII reactivity in
RA. To avoid any confusion, it needs to be stressed that RA is
a heterogeneous syndrome in which not only CII, but also other
cartilage proteins and other mechanisms are of importance.
Such a pathogenic heterogeneity is reflected by the multitude
of experimental animal models that have demonstrated how
many different pathways may lead to arthritis [25].
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Figure 1
The immunodominant CII 256–270 peptide. CII is variably post-
translationally modified in the chondrocyte by hydroxylation followed by
galactosylation or glucogalactosylation of hydroxylysines. The peptide
is depicted with the O-linked b-galactose at position 264
(hydroxylysine). The MMC mice have the CII point mutation to express
glutamic acid at position 266 (as in human and rat CII), whereas
mouse CII expresses aspartic acid at this position.
Figure 2
Incidence of arthritis in male mice. Triangles represent transgenic
MMC mice and squares represent nontransgenic littermates. Open
and filled symbols represent thymectomized (Tx) and sham-operated
(Sham) mice, respectively.Introduction
T cells originate from multipotent cells in the bone marrow,
but mature in the thymus. They are educated in the thymus
both by positive selection (ie in which only the thymocytes
that are capable of interacting with self-MHC survive [26])
and by negative selection (ie in which recognition of self-
antigens that are present in the thymus leads to apoptosis
[27]). After approximately 2 weeks the T cells leave the
thymus as mature but naïve cells [28]. Outside the thymus
T cells circulate in search for a peptide–MHC complex to
recognize. If a naïve T-cell fails to find such an antigenic
complex its lifespan will be limited [29]. Instead, new
T cells will continuously emerge from the thymus and
replace the ones leaving the pool of naïve T cells.
The extent to which the lifespan is prolonged if such
T cells meet their antigen is currently under debate. One
possibility is that naïve T cells may only respond to anti-
gens that are presented by professional APCs and in the
proper microenvironment; potential antigens that are
located in other cells and tissues are ignored [30]. Alter-
natively, some T cells may interact with antigens outside of
the context of an immune response (eg in the physiologi-
cal state by self-antigens presented for the T cells in drain-
ing lymph nodes). Recent data [31,32] suggest that a
low-affinity interaction, for example by the appropriate
MHC but without the relevant peptide, will lead to the pro-
longation of the lifespan of newly exported naïve T cells.
Other findings suggest that the transgenic expression of
foreign antigen in peripheral tissues will lead to maintained
survival of transgenic T cells with a tolerized phenotype
[33]. The importance of such T cells in autoimmune
disease is of great significance, but their existence and
function are still obscure.
Target antigens, which are of importance for development
of autoimmune disease, may evoke either ignorance or tol-
erance. For example, in mice that are transgenic for a
T-cell receptor (TCR) that is specific for myelin basic
protein (MBP), which is a central nervous system-specific
protein, the T cells ignore the existence of the antigen
unless they are not activated by other means [34,35]. In
other autoimmune diseases, however, the relevant self-
tissue is more readily exposed to the immune system and
consequently a pool of T cells that recognize the self-
antigen, but which fail to be deleted, might exist. We
believe that RA, as well as CIA, which is an experimental
model of RA, are such diseases.
Both RA and CIA show MHC class II association, whereby
CIA in mice is associated with the Aq molecule expressed
by the H-2q haplotypes [36] and RA in humans with the
DRB1*0401/DRA molecule in the DR4 haplotype [37,38].
Interestingly, the MHC association indicates structural
relevance, because the peptide binding cleft of the Aq and
the DRB1*0401/DRA molecule are very similar and bind
peptides from the same CII region [39,40]. Consequently,
mice that express the DRB1*0401/DRA molecule are sus-
ceptible to CIA [5,41]. The MHC class II association pro-
vides a strong indication that the model is T-cell
dependent [42–44].
CIA is not only a useful model for RA, but is also a valu-
able tool for studying the interactions between the immune
system and cartilage. CII is the major protein constituent
of cartilage, and is highly conserved, with only minor amino
acid substitution between species. When comparing the
triple helical region of mouse [45] and rat [46] CII, only 13
out of 1015 amino acids were substituted. CII is further
subjected to extensive post-translational modifications,
including hydroxylation of prolines and lysines and glyco-
sylation of hydroxylysines.
There are only a few reports in the literature in which gly-
copeptides were involved in immune responses [47–51],
and the present CII 256–270 peptide is the only one that
is naturally selected [52,53]. When H-2q mice are immu-
nized with rat CII, a T-cell response toward CII 256–270
is elicited. This T-cell epitope contains three sites for
hydroxylations and two sites for glycosylations [2], and
these modifications participate in the immune response.
To study self-tolerance of CII 256–270 reactive T cells,
we previously generated mice with transgenic, cartilage-
specific expression of the rat CII epitope [14]. These
MMC transgenic mice have a reduced susceptibility to rat
CIA; only 45% of the mice develop a severe polyarthritis
after immunization, as compared with 95% of the non-
transgenic littermates. The decreased incidence of CIA
can be explained by T-cell tolerance, because the immun-
odominant T-cell epitope from rat CII is now expressed as
self in cartilage. The existence of immune tolerance
towards glycopeptides has not been addressed before,
and is an important issue because glycosylated CII is
more arthritogenic than nonglycosylated CII [52].
The present study was designed to investigate whether
tolerized T cells are capable of mediating disease or
whether naïve T cells, that are not yet tolerized, make a
necessary contribution to pathology. Although the thymus
shrinks with age, it continues to produce fresh thymus
emigrants (ie naïve T cells). If these are specific for a
distant tissue-specific self-antigen we postulated that it
would take time before the T cells acquired tolerance.
Possibly, the arthritis in the transgenic mice could occur
as a result of the encounter of such nontolerized T cells
with the immunogenic CII, rather than first being tolerized
by the CII derived from cartilage. To address this possibil-
ity we thymectomized adult mice and immunized them with
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Full articleCII after 4 weeks, thereby allowing the T cells to become
tolerized. The results indicate that the tolerized T cells
themselves could be involved in the development of arthri-
tis. We also studied immune responses in lymph node cul-
tures derived from thymectomized mice, and showed
T-cell tolerance toward the glycosylated version of the CII
256–270 epitope. In spite of peripheral tolerance this
peptide elicited IFN-g production, which we believe is
important for disease development.
Materials and methods
Mice
C3H.Q mice (H-2q) were originally a gift from Dr DC
Shreffler, St Louis, USA; DBA/1 mice originated from the
Jackson Lab (Bar Harbor, Maine, USA); and B10.Q mice
(H-2q) were from Dr Jan Klein, Tübingen, Germany. All
arthritis and in vitro experiments were performed on F1
animals (B10.Q×C3H.Q). The transgenic MMC-1 mice (in
this work referred to as MMC mice) have previously been
described [14]. Briefly, the MMC mouse, which was origi-
nally from the C3H.Q background, was back-crossed eight
generations to the B10.Q mice (MMC-BQ). The MMC
transgene is a mutated mouse CII gene, in which position
266 has been changed from a D into an E, thereby contain-
ing the rat CII 256-270 epitope and showing cartilage-
restricted expression. Nontransgenic QD mice
(B10.Q×DBA/1) F1 were used for the establishment of a
CII-specific T-cell line. MMC-QD mice were used in trans-
fer experiments as recipient mice for migration studies. All
animals were bred and used in our animal facilities.
Antigens
Rat CII was prepared from the SWARM chondrosarcoma
by pepsin digestion [54], and further purified as previously
described [55]. The peptides were synthesized as previ-
ously described [2], the glycosylated CII 256–270 peptide
with a b-D-galactopyranose residue on L-hydroxylysine at
position 264 (Fig. 1) [56]. Both collagen and collagen pep-
tides were dissolved and stored in 0.1mol/l acetic acid.
Thymectomy, immunization and arthritis evaluation
Adult mice (7 weeks old) were thymectomized under
anaesthesia. In parallel, mice were also sham-operated
under the same conditions. The mice were allowed to
recover for 4 weeks before CII immunization. The mice
were immunized intradermally in the base of the tail with
100mg rat CII emulsified 1:1 in complete Freund’s adju-
vant (IFA; Difco, Detroit, MI, USA). They were also
boosted with 50mg rat CII emulsified 1:1 in IFA (Difco),
5 weeks later. At that time blood samples were also taken
for analysis of anti-CII antibody responses. The amounts of
total anti-CII IgG as well as the IgG1 and IgG2a isotypes
were determined through quantitative ELISA [57]. Using
this assay no CII antibody reactivities may be found in
either wild-type or MMC transgenic mice before immuniza-
tion. Development of clinical arthritis was followed through
visual scoring of the mice, starting 2 weeks after immu-
nization and continuing until the end of the experiment.
The arthritis was scored using a scale of 1–3 (1, one
affected joint; 2, two or more arthritic joints; and 3, severe
arthritis involving the entire paw), giving a maximum score
of total 12 per individual.
Lymphocyte assays
To assay T-cell effector functions, mice were immunized in
the hind footpads with 50mg rat CII emulsified 1:1 in com-
plete Freund’s adjuvant and the draining popliteal lymph
nodes were taken 10 days later. The LNCs were used for
proliferation assay, IFN-g ELISA and B-cell ELISPOT. For
the proliferation assay, 106 cells were put in triplicate cul-
tures in microtitre wells together with antigen and incu-
bated for 72 h before thymidine-labelling and harvesting
15–18 h later. For IFN-g ELISA, supernatant from the pro-
liferation plates was removed before harvesting and used
in an ELISA to quantify the amount of IFN-g produced, as
previously described [15]. B-cell ELISPOT analyses were
performed as previously decribed (but with minor modifi-
cations) [16] in order to enumerate the number of cells
that produce anti-CII IgG. In all experiments the LNCs
were assayed from individual mice and statistics were cal-
culated from the biological variation.
T-cell lines and CFSE assay
A T-cell line that is reactive toward rat CII was established
by immunization of QD mice with rat CII in the hind foot-
pads. Eight days later draining lymph nodes were col-
lected and restimulated in vitro with rat CII for 4 days.
After 4 days of antigen stimulation, cells were collected,
washed and allowed to rest in the absence of APCs and
in the presence of IL-2 for 1 week. Thereafter the T cells
were restimulated with freshly collected, irradiated (3000
Rad), syngenic spleen cells and rat CII for 3 days (5×105
T cells/ml, 5×106 APCs/ml, 10mg rat CII/ml) followed by
2 weeks of resting in IL-2-containing medium. At the time
of restimulation, an aliquot of the cell line was also tested
for antigen specificity. The cell line responded toward
denatured CII, the nonmodified CII 256–270 peptide and
the glycosylated CII 256–270 peptide with proliferation
and IFN-g production (data not shown). This scheme of 2-
weekly restimulation cycle was repeated a further two
times before transferring the cells to recipient mice.
Because our purpose was to follow the migration pattern
of CII-specific T cells in vivo, and not transfer of disease,
the cells were allowed to rest without APCs or antigen in
vitro for 7 days after restimulation in the presence of IL-2
before transfer. The cells were phenotypically character-
ized at this stage, and were found to be CD4-positive with
high and intermediate expression of CD54 and CD69,
respectively, and low expression of CD25 and CD95
ligand. Immediately before transfer, the cells were labelled
with the cytoplasmic dye CFSE (Molecular Probes,
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the cells with 5mmol/l CFSE at 37°C. Labelled cells (107)
were then injected intravenously into transgenic MMC
mice and nontransgenic littermates. The mice were sacri-
ficed 4 days after cell transfer and the frequency of CFSE-
labelled cells were determined by flow cytometry with a
fluorescence-activated cell sorter and using CellQuest
Software (Becton Dickinson, Mountain View, CA, USA).
Statistical analysis
Incidence of arthritis was analyzed using the c2 test, and
antibody levels and proliferative responses were analyzed
using the Mann–Whitney U-test.
Results
Thymectomized mice develop CIA with the same features
as nonthymectomized animals
Seven-week-old mice were thymectomized or sham-oper-
ated. Four weeks later the mice were immunized to induce
CIA and disease was scored for the following 10 weeks.
Clearly, the thymectomized MMC mice were susceptible
to arthritis (five out of 18 developed arthritis). No signifi-
cant differences in susceptibility between thymectomized
and sham-operated mice, or between males and females,
were seen (Fig. 2, Table 1). In concordance with earlier
results [14], MMC transgenic mice had a significantly
reduced susceptibility to arthritis as compared with the
nontransgenic littermates (P<0.0001 for arthritic scores,
disease onset and incidence). Disease incidence in the
transgenic mice was even lower than has previously been
found, which is most likely due to the change of gene
background from C3H.Q to (B10.Q×C3H.Q) F1. A
similar reduction in incidence was also observed in
(B10.RIII×C3H.Q) F1 MMC transgenic mice [36].
Antibody responses
All mice were bled at 35 days after immunization, and the
total levels of anti-CII IgG determined. As shown in Table 1,
transgenic mice developed significant levels of anti-CII IgG,
but the antibody titres were lower than in nontransgenic lit-
termates (P<0.0001). An effect on the antibody levels by
thymectomy could not be observed, and neither did the
thymectomy affect the distribution of IgG1 titres versus
those of IgG2a (Fig. 3), indicating that the observed toler-
ance is not associated with a shift from a T-helper-1- to a
T-helper-1-like immune response. Only four animals had
more IgG1 than IgG2a antibodies, two with arthritis (one
transgenic and one littermate) and two without clinical
disease (one transgenic and one littermate).
Lymph node cultures
Antigen-specific T-cell activation was investigated at dif-
ferent time points after thymectomy to determine whether
the mice harboured tolerized or naïve T cells. The mice
were immunized with rat CII, and 10 days later the recall
response was determined toward the nonglycosylated CII
256–270 peptide, the glycosylated CII 256–270 peptide
and purified protein derivative (Fig. 4). The galactosylated
form of the peptide (Fig. 1) was used because this is the
most immunodominant modification [18].
LNCs from transgenic mice proliferated poorly in response
to CII peptides, indicating that these cells had been
specifically tolerized, which is in accordance with earlier
observations (Fig. 4) [14]. Nevertheless, the proliferative
response to the glycosylated peptide was still significant
(P=0.002 versus background values, and P=0.003
versus the response toward the nonglycosylated peptide
as analyzed in all mice), suggesting that the remaining
response is directed toward this peptide. Most important,
however, was that the proliferative response in the trans-
genic mice did not decrease after thymectomy.
The supernatants of the proliferation cultures were also
analyzed for IFN-g content (Fig. 4). The response was
somewhat reduced compared with that observed in non-
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Table 1
Development of CIA and antibody responses to CII
Arthritis Onset (day Anti-CII IgG (mg/ml
(frequency of max score of in serum 35 days 
Sex Mice CIA) arthritic mice) Severity after immunization)
Male Lm Sham 11/11 25 ± 4 8.4 ± 1.5 182 ± 73
Tx 9/9 33 ± 9 9.1 ± 2.0 328 ± 206
MMC Sham 2/8 34 ± 6 4.5 ± 5.0 63 ± 112
Tx 3/8 56 ± 22 2.0 ± 1.0 40 ± 49
Female Lm Sham 6/7 35 ± 15 7.2 ± 2.8 614 ± 413
Tx 7/8 43 ± 16 7.6 ± 3.0 423 ± 273
MMC Sham 0/8 – – 30 ± 25
Tx 2/10 64 ± 1.4 3.0 ± 2.8 24 ± 33
lm, nontransgenic littermates; Sham, sham-operated; Tx, thymectomized. Where applicable, values are expressed as mean ± standard deviation.transgenic littermates, notably when comparing the
response towards the nonglycosylated peptide. Again, no
reduction in the IFN-g response was observed after
thymectomy. In fact, a significant response towards the
nonglycosylated peptide was observed in mice immu-
nized 8 weeks after thymectomy. Still, this response was
very much reduced in comparison with that induced with
the glycosylated peptide or with that observed in non-
transgenic littermates.
In summary, the autoimmune response in transgenic
animals did not decrease after thymectomy, showing that
these T cells were not newly exported, but were main-
tained after being partially tolerized. LNCs from transgenic
mice produced less IFN-g than the nontransgenic litter-
mates in response to the nonglycosylated CII 256–270
peptide, as previously reported for MMC mice with intact
thymus. The time after thymectomy (4 or 8 weeks) did not
attenuate the autoimmune response to the nonglycosy-
lated or the glycosylated peptide. Thus, the responses
were still significant 8 weeks after thymectomy.
In similarity with the observed T-cell responses, significant
numbers of B cells producing anti-CII IgG were seen in
CII-immunized MMC mice using quantitative ELISPOT
assays (Fig. 5). The response did not decrease after
thymectomy. Together with the data shown in Figure 3,
these data show that the significant, but reduced antibody
levels to CII in the MMC mouse is reflected by numbers of
antibody-secreting cells. In comparison with earlier data
using the MMC transgenic mice, this was a more pro-
nounced reduction in the B-cell response. The different
genetic background of the mice used in the present study
may explain this, in which an F1 with the relatively low
responder B10 background was used. Again the same
phenomenon was observed in (B10.RIII×C3H.Q) F1
transgenic mice immunized with rat CII [46].
In vivo transfer of rat collagen type II-reactive T cells
An activated CFSE-labelled T-cell line, which was reactive
towards rat CII, was transferred into mice to follow T-cell
migration and survival. Four days after cell transfer the
transgenic mice had dramatically fewer CFSE-labelled
cells in the spleen than did nontransgenic littermates
(Fig. 6a); similar reduced numbers of CFSE-labelled cells
were also seen in blood (data not shown). Only occasion-
ally could cells be detected in the lymph nodes or in the
thymus. These had only one fluorescence peak, indicating
that they had not proliferated in vivo. Extracted spleen
cells were analyzed for phenotypic markers, such as
CD71, CD69 and CD43. CFSE-labelled cells stained
positive for CD43 and negative for CD71, and approxi-
mately 50–70% were CD69 positive (Fig. 6b, and data
not shown). However, there was no difference in the
expression levels of these activation markers between
cells transferred into MMC or nontransgenic mice.
The dramatic differences in detectable events in the
spleen and blood between MMC and littermate recipients
suggest that the T cells interacted with the antigens that
were present in MMC mice, but that this did not occur in
their nontransgenic littermates.
Discussion
In the present study we showed that T cells that are spe-
cific for a tissue-specific matrix protein, CII, are partially
tolerized and that these cells are maintained after thymec-
tomy. By adult thymectomy, the continuous outflow of
naïve T cells in mice with an established, normal T-cell
repertoire was terminated. Still, the partial tolerant state,
defined by lack of proliferative capacity but with significant
IFN-g response and B-cell helping capacity, was
http://arthritis-research.com/content/2/4/315
Figure 3
Serum levels of antibodies specific for CII. Comparison of isotype anti-
CII IgG responses in thymectomized (Tx) and sham-operated (Sham)
mice as measured in sera 35 days after immunization in MMC
transgenic mice and the nontransgenic littermates. Open symbols
represent IgG2a and filled symbols IgG1. The transgenic mice have
significantly lower isotype levels compared with their nontransgenic
littermates, but thymectomy had no effect. The same pattern was seen
in female (A) and male (B) mice.maintained up to 8 weeks after thymectomy. In addition,
thymectomy did not affect the susceptibility to CIA,
suggesting that the partially tolerant T cells are involved in
development of arthritis.
The loss of detectable CFSE-labelled rat CII reactive
T cells in MMC mice suggests that the T cells had encoun-
tered their antigen. However, where this interaction takes
place and the outcome of it was not deduced in the
present study. It may be speculated that the interaction
takes place in the circulation due to the inability of T cells
to reach lymph nodes (the T-cell line is CD62 ligand nega-
tive; data not shown). Furthermore, the rapid decrease in
cell numbers implies that this interaction occurs shortly
after cells enter the periphery. However, it could also be
caused by a migration of T cells into tissue, even in the
absence of local inflammation, which would promote such
traffic. If the T cells do migrate out into the tissue the
outcome could possibly be retention and even expansion
of the T-cell population, and the latter may even lead to
outbreak of arthritis. Importantly, we showed that rat CII-
reactive T cells interact with the antigen present in MMC
mice, because fewer cells are found 4 days after cell
transfer in transgenic mice compared with in control
animals.
These findings suggest that the immune system normally
interacts with cartilage and that the T cells that participate
in such an interaction survive and have maintained func-
tion. The questions that arise are when, how and where
the T cells and the CII antigen normally meet.
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Figure 5
B-cell response to CII. IgG ELISPOT is an assay that enumerates the
number of anti-CII antibody-producing cells present in the LNCs.
Squares represent individual nontransgenic littermates and triangles
represent the transgenic MMC mice. No difference before and after
thymectomy was noted and the difference between MMC and wild-
type mice are significant (P=0.0012 for all mice, P=0.0102 for
thymectomized mice). TX, thymectomized.
Figure 4
T-cell response to CII. Influence of thymectomy (Tx) on the T-cell response to CII peptides of MMC or littermate (lm) mice. Activation of lymph node
cultures with different antigens; 50 mg/ml synthetic CII 256–270 peptide, 50 mg/ml glycosylated CII 256–270 peptide, 10mg/ml purified protein
derivative. Backgrounds are cultures in which no antigen was added. The results after stimulation with purified protein derivative (positive control)
are shown in the left, proliferative response towards CII peptides are shown in the middle and the IFN-g production is shown in the right part of the
figure, respectively. The background IFN-g values below 0.01U/ml are not indicated in the figure. At the indicated times after thymectomy (4 weeks
[4w] or 8 weeks [8w]), the indicated number of mice were immunized with rat CII and 10 days later the LNCs were isolated. Each bar represents
the mean value ±standard error. Both proliferation (as measured with thymidine uptake) and IFN-g contents in the supernatants are indicated.
*P<0.05, **P<0.01, ***P<0.001, versus background.Presumably the interaction takes place in the lymph
nodes that drain the joints, and depends on the amount
of CII that is degraded and transported to these lymph
nodes, the nature of the transporting APCs and the
MHC-binding efficiency after processing. There is no lym-
phatic drainage of cartilage, but the surrounding synovial
tissue contains numerous macrophages that have the
capacity to engulf proteins scavenged from cartilage. It is
likely, but not proven, that some of these macrophages
transport CII to lymph nodes and present them to the
immune system. It is not likely that synovial dendritic cells
fulfil these functions, because dendritic cells do not
present collagen [58,59], in contrast to the crucial role of
dendritic cells to prime immune responses to other anti-
gens [60]. Thus, the presentation of CII in the periphery is
limited but must occur.
The circulation of newly exported T cells is most likely very
rapid, but the possibility of T cells encountering specific
antigens is of course also limited by the low numbers of
CII-reactive T cells. If tolerance is an important mechanism
for protection from immune-mediated inflammatory attacks
on self-tissues, it should be important to allow the interac-
tions between self-reactive T cells and the respective self-
antigens to occur as quickly as possible. In this context, 4
weeks is a long time for a circulating T cell. Studies on
class I restricted CD8+ T cells [31,61] have shown that
naïve T cells exported from thymus will not expand unless
they meet their specific antigen. However, they may
survive for at least 2 weeks but will subsequently disap-
pear. Memory cells on the other hand are more easily
maintained, even in the absence of antigen. The lifespan of
CD4+ T cells is more controversial, but their survival is
probably more limited than for CD8+ T cells. The mainte-
nance of memory CD4+ T cells has been suggested [62]
to be dependent on the continuous presence of the spe-
cific antigen. In the case of the CII-reactive T cells, the
specific antigen is in the cartilage and encounters with this
antigen may lead to maintenance, which most likely is syn-
onymous with ‘partial’ tolerance induction.
We describe the observed tolerance as ‘partial’ because
we have no better word for the observed state. The
description is made on the population level, and not on the
cellular level. Thus, the observed partial tolerance could
have different explanations. One possibility is tolerization
on the cellular level, for instance, by induction of a different
mode of signalling through TCR or through costimulatory
molecules [63]. Alternatively, the tolerance could be
achieved by deletion of T cells that express TCRs with
high avidity for the CII peptide, leaving only the low-avidity
T cells, which might reach the critical threshold for ‘partial’
activation (IFN-g secretion and B-cell help, but no IL-2
secretion). Nevertheless, if this should be the case the
triggered low avidity CII-reactive cells are maintained and
play a role in arthritis.
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Figure 6
Fate of CII-reactive T cells in vivo using transferred CFSE-labelled rat
CII-reactive T cells. (a) The rat CII-reactive T cells could not be seen to
divide in vivo. In MMC transgenic mice, however, dramatically fewer
CFSE-positive cells could be recovered, all of which were
CD43-positive. (b) One representative experiment (out of three) for
two-colour analysis of spleen cells from MMC transgenic mice and
nontransgenic littermates for CFSE and CD43.Interestingly, the glycosylated peptide elicited a stronger
recall response than the synthetic peptide, which is in
accordance with the finding that glycosylated CII is more
arthritogenic than nonglycosylated CII [52]. How can such
a finding be explained? One possibility is that the stronger
response to the glycosylated peptide reflects a greater
number of various TCRs (and thus T cells) that are
capable of interacting with the glycosylated peptide, pos-
sibly because of the sugar being quite flexible in its posi-
tion. Alternatively, the expression level of the glycosylated
epitope will also influence tolerance induction. If there is
low expression of this variant, less glycopeptide-specific
T cells will become tolerized in vivo. It should also be
emphasized that the glycopeptide-specific T cells, which
may recognize a structure much larger than any amino
acid side chain, are apparently efficiently selected in the
thymus, despite the absence of the relevant peptides. The
structural basis of the positive selection of these T cells
remains to be clarified.
The role of long-lived self-reactive T cells in mediating
effector functions is of course a central issue in the under-
standing of chronic autoimmune disease. The location and
the physical state of the relevant self-antigen will, to a
large extent, determine the activity of such T cells. In
experimental allergic encephalomyelitis (EAE), an animal
model for multiple sclerosis, an interesting study [64] has
been reported on the breakage of tolerance. Mice were
administered the MBP peptide Ac1-11, and developed a
severe and acute encephalomyelitis. After recovering from
disease the mice were given a superantigen that was
reactive to the same subtype of T cells that initially medi-
ated disease. These T cells were now tolerant, but the
superantigen was able to break this tolerance and the
mice suffered a second exacerbation of disease. Thus,
T cells that are specific for EAE seem normally to ignore
the existence of the self-antigen unless they are activated,
which leads to trafficking into the central nervous system
and subsequently to induction of disease. Consequently,
the recall T-cell response to MBP is as strong to self-MBP
as to foreign MBP. In contrast, the recall response to CII
differs dramatically between self-CII and foreign CII due to
tolerance induction to the CII 256–270 peptide, which is
derived from cartilage.
From the above-stated reasons it is likely that tolerance to
cartilage-derived collagen peptides expressed on APCs in
peripheral lymphoid organs, but not in the thymus, occurs.
When tolerance is broken, for example after the introduc-
tion of adjuvant, which will activate APCs, autoimmune
disease can ensue. At present we know very little regard-
ing what can cause breakage of tolerance. In mice we
often immunize with tissue-specific proteins in the pres-
ence of adjuvant or with adjuvant only [65], but what
happens in humans with autoimmune diseases that are
triggered by unknown causes? Peripheral tolerance
towards tissue-restricted antigens in mice may include dif-
ferent routes of tolerance induction and maintenance [33].
Knowledge about such mechanisms would certainly help
in understanding the basic mechanisms that cause
autoimmune disease and will provide possibilities to
control and limit the chronic development of pathologic
inflammation.
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